In summary, research reviewed clearly suggests that, although CBD, that is approved for treating epilepsy in young children, and in combination with THC as Sativex, for treating symptoms of multiple sclerosis, and has potential to treat a wide range of clinical indications, there is insufficient clinical evidence to support the use of cannabis or its highly advertised product-CBD in the treatment of COVID-19-asociated mental health or neuropsychiatric complications at this time. More systematic evaluation of cannabis or CBD in large clinical trials is essential prior to endorsing wider use of CBD or other cannabis products for alleviation of mental health symptomatology.